Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlType 2 DiabetesIssue 543

Structured Blood Glucose Testing with Pattern Analysis Improves Blood Sugars

Structured self-monitored blood glucose with pattern analysis has been associated with greater reductions in A1c. It also requires less testing than the standard approach, and promotes more timely and aggressive treatment changes in poorly controlled, non-insulin-treated patients with Type 2 diabetes, according to study results....

Advertisement

Lead author Pamela Kushner, MD, Long Beach, California, stated that, the 12-month, randomized, controlled, multicentre study assessed the effect of structured testing on results of HbA1c.

In all, 483 insulin-naïve subjects were selected based on their poorly controlled (HbA1c >= 7.5%) Type 2 diabetes. The patients were randomized into 2 divisions: usual care in the Active Control Group or usual care with a minimum quarterly use of structured testing with pattern analysis in the Structured Testing Group. All patients were instructed to monitor their blood glucose as usual, based on their healthcare providers' instructions, but Structured Testing Group members were also instructed on recording blood glucose levels, food eaten, and energy levels as well as pattern analysis. Patients in the Structured Testing Group had to complete a 3-day structured testing session, involving 7 tests per day, prior to quarterly visits, and all patients were seen at least once quarterly as well as performing self-monitored blood glucose between study visits.

Both groups did have significant reductions in HbA1c over the trial period, but an intent-to-treat analysis showed greater reductions in the Structured Testing Group than in the Active Control Group (-1.2% vs. -0.9%, P =.04). Furthermore, mean daily blood glucose tests were significantly lower for the Structured Testing Group than the Active Control Group at 6, 9, and 12 months (P =.007,.001, and.0004, respectively), reported Dr. Kushner.

Structured Testing Group healthcare providers were 31% more likely to recommend at least 1 medical treatment change at the first treatment visit 1 month post baseline, 33% were more likely to recommend lifestyle adjustments, and 33% were more likely to recommend a combination of the two (P =.0001). Subjects who received this treatment change at the first visit were able to achieve a significantly larger HbA1c reduction than those who did not receive a recommendation. "And they were significantly less likely to have clinical inertia," Dr. Kushner added.

Ultimately, the researchers concluded that "early treatment changes are linked to significant glycemic improvement over 12 months, and may be a major reason why subjects in the Structured Testing Group evidenced a significantly greater reduction in HbA1c than Active Control Group subjects." Dr. Kushner also noted that patients and physicians reported that they "liked having the ability to track patterns in their results based on their behavior."

For a copy of the form used by the patients for the pattern analysis see our Tool for Your Practice, 360 View -- A Simple Blood Glucose Analysis System (PDF).

[Structured Blood Glucose Testing Leads to Improvements in HbA1c in Patients With Poorly Controlled, Non-Insulin-Treated Type 2 Diabetes. Results from the Structured Testing Program (STeP) Study. Abstract P058]

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 10 October, 2010 and appeared in  BG ControlType 2 DiabetesIssue 543

Past five issues: Issue 796 | Diabetes Clinical Mastery Series Issue 255 | Issue 795 | SGLT-2 Inhibitors Special Edition August 2015 | Diabetes Clinical Mastery Series Issue 254 |

2015 Most Popular Articles:

Coffee Consumption Proves Potential in Reducing Type 2 Diabetes Risk
Posted August 07, 2015
Impaired Glucose Uptake in the Brain May Increase Alzheimer's Disease Risk
Posted August 07, 2015
Ketoacidosis Not as Great as Thought in Diabetes Patients Taking Invokana
Posted August 13, 2015
First Non-Surgical Weight Loss Procedure for Mild-to-Moderate Obesity
Posted August 07, 2015
Impact of Switching Insulin Glargine to Insulin Detemir in T2 Patients
Posted August 14, 2015
SIgnificant Weight Gain Associated with Laparoscopic Sleeve Gastrectomy
Posted August 14, 2015
GLP-1 Agonist Semaglutide Completes Phase III Trial with Positive Results
Posted August 07, 2015
Diabetes Combination Drug LixiLan Meets Main Target in Late Stage Trial
Posted August 07, 2015
Two New Possible Methods for Diagnosing and Monitoring Diabetes
Posted August 07, 2015
Soybean Oil Causes More Obesity and Diabetes Than Fructose
Posted August 20, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
What percentage of your patients have reached goal for A1c, BP and cholesterol?

CME/CE of the Week
Category: Diabetic Foot
CE Credits: .75